Multi-omics machine learning to study host-microbiome interactions in early-onset colorectal cancer.


Journal

NPJ precision oncology
ISSN: 2397-768X
Titre abrégé: NPJ Precis Oncol
Pays: England
ID NLM: 101708166

Informations de publication

Date de publication:
17 Jul 2024
Historique:
received: 25 02 2024
accepted: 09 07 2024
medline: 18 7 2024
pubmed: 18 7 2024
entrez: 17 7 2024
Statut: epublish

Résumé

The incidence of early-onset colorectal cancer (eoCRC) is rising, and its pathogenesis is not completely understood. We hypothesized that machine learning utilizing paired tissue microbiome and plasma metabolome features could uncover distinct host-microbiome associations between eoCRC and average-onset CRC (aoCRC). Individuals with stages I-IV CRC (n = 64) were categorized as eoCRC (age ≤ 50, n = 20) or aoCRC (age ≥ 60, n = 44). Untargeted plasma metabolomics and 16S rRNA amplicon sequencing (microbiome analysis) of tumor tissue were performed. We fit DIABLO (Data Integration Analysis for Biomarker Discovery using Latent variable approaches for Omics studies) to construct a supervised machine-learning classifier using paired multi-omics (microbiome and metabolomics) data and identify associations unique to eoCRC. A differential association network analysis was also performed. Distinct clustering patterns emerged in multi-omic dimension reduction analysis. The metabolomics classifier achieved an AUC of 0.98, compared to AUC 0.61 for microbiome-based classifier. Circular correlation technique highlighted several key associations. Metabolites glycerol and pseudouridine (higher abundance in individuals with aoCRC) had negative correlations with Parasutterella, and Ruminococcaceae (higher abundance in individuals with eoCRC). Cholesterol and xylitol correlated negatively with Erysipelatoclostridium and Eubacterium, and showed a positive correlation with Acidovorax with higher abundance in individuals with eoCRC. Network analysis revealed different clustering patterns and associations for several metabolites e.g.: urea cycle metabolites and microbes such as Akkermansia. We show that multi-omics analysis can be utilized to study host-microbiome correlations in eoCRC and demonstrates promising biomarker potential of a metabolomics classifier. The distinct host-microbiome correlations for urea cycle in eoCRC may offer opportunities for therapeutic interventions.

Identifiants

pubmed: 39020083
doi: 10.1038/s41698-024-00647-1
pii: 10.1038/s41698-024-00647-1
doi:

Types de publication

Journal Article

Langues

eng

Pagination

146

Informations de copyright

© 2024. The Author(s).

Références

Cancer of the colon and rectum—cancer stat facts. SEER. https://seer.cancer.gov/statfacts/html/colorect.html .
Wolf, A. M. D. et al. Colorectal cancer screening for average-risk adults: 2018 guideline update from the American Cancer Society. CA Cancer J. Clin. 68, 250–281 (2018).
pubmed: 29846947 doi: 10.3322/caac.21457
Kamath, S. D. et al. Racial disparities negatively impact outcomes in early‐onset colorectal cancer independent of socioeconomic status. Cancer Med. 10, 7542–7550 (2021).
pubmed: 34647438 pmcid: 8559495 doi: 10.1002/cam4.4276
Siegel, R. L. et al. Colorectal cancer statistics, 2020. CA Cancer J. Clin. 70, 145–164 (2020).
pubmed: 32133645 doi: 10.3322/caac.21601
Giannakis, M. & Ng, K. A common cancer at an uncommon age. Science. 379, 1088–1090 (2023).
pubmed: 36927016 doi: 10.1126/science.ade7114
Eng, C. et al. A comprehensive framework for early-onset colorectal cancer research. Lancet Oncol. 23, e116–e128 (2022).
pubmed: 35090673 doi: 10.1016/S1470-2045(21)00588-X
Spaander, M. C. W. et al. Young-onset colorectal cancer. Nat. Rev. Dis. Prim. 9, 21 (2023).
pubmed: 37105987 doi: 10.1038/s41572-023-00432-7
Weinberg, B. A. & Marshall, J. L. Colon cancer in young adults: trends and their implications. Curr. Oncol. Rep. 21, 3 (2019).
pubmed: 30659375 doi: 10.1007/s11912-019-0756-8
Kong, C. et al. Integrated metagenomic and metabolomic analysis reveals distinct gut-microbiome-derived phenotypes in early-onset colorectal cancer. Gut gutjnl-2022-327156. https://doi.org/10.1136/gutjnl-2022-327156 (2022).
Irajizad, E. et al. A blood-based metabolomic signature predictive of risk for pancreatic cancer. Cell Rep. Med. 4, 101194 (2023).
pubmed: 37729870 pmcid: 10518621 doi: 10.1016/j.xcrm.2023.101194
Barot, S. V. et al. Distinct intratumoral microbiome of young-onset and average-onset colorectal cancer. eBioMedicine 100, 104980 (2024).
pubmed: 38306898 pmcid: 10850116 doi: 10.1016/j.ebiom.2024.104980
Jayakrishnan, T. et al. Plasma metabolomic differences in early-onset compared to average-onset colorectal cancer. Sci. Rep. 14, 4294 (2024).
pubmed: 38383634 pmcid: 10881959 doi: 10.1038/s41598-024-54560-5
Yoon, G., Gaynanova, I. & Müller, C. L. Microbial networks in SPRING—semi-parametric rank-based correlation and partial correlation estimation for quantitative microbiome data. Front. Genet. 10, 516 (2019).
pubmed: 31244881 pmcid: 6563871 doi: 10.3389/fgene.2019.00516
Stockert, J. A., Weil, R., Yadav, K. K., Kyprianou, N. & Tewari, A. K. Pseudouridine as a novel biomarker in prostate cancer. Urol. Oncol. 39, 63–71 (2021).
pubmed: 32712138 doi: 10.1016/j.urolonc.2020.06.026
DeGuzman, A., Lorenson, M. Y. & Walker, A. M. Bittersweet: relevant amounts of the common sweet food additive, glycerol, accelerate the growth of PC3 human prostate cancer xenografts. BMC Res. Notes 15, 101 (2022).
pubmed: 35272680 pmcid: 8908677 doi: 10.1186/s13104-022-05990-9
Koundouros, N. & Poulogiannis, G. Reprogramming of fatty acid metabolism in cancer. Br. J. Cancer 122, 4–22 (2020).
pubmed: 31819192 doi: 10.1038/s41416-019-0650-z
Zhu, G. et al. Untargeted GC-MS-based metabolomics for early detection of colorectal cancer. Front. Oncol. 11, 729512 (2021).
pubmed: 34804922 pmcid: 8599589 doi: 10.3389/fonc.2021.729512
Sakai, M. et al. Arachidonic acid and cancer risk: a systematic review of observational studies. BMC Cancer 12, 606 (2012).
pubmed: 23249186 pmcid: 3574856 doi: 10.1186/1471-2407-12-606
Chhetri, D. R. Myo-inositol and its derivatives: their emerging role in the treatment of human diseases. Front. Pharmacol. 10, 1172 (2019).
pubmed: 31680956 pmcid: 6798087 doi: 10.3389/fphar.2019.01172
Xu, C. et al. FADS1-arachidonic acid axis enhances arachidonic acid metabolism by altering intestinal microecology in colorectal cancer. Nat. Commun. 14, 2042 (2023).
pubmed: 37041160 pmcid: 10090135 doi: 10.1038/s41467-023-37590-x
Yang, Z., Tang, H., Lu, S., Sun, X. & Rao, B. Relationship between serum lipid level and colorectal cancer: a systemic review and meta-analysis. BMJ Open 12, e052373 (2022).
pubmed: 35732386 pmcid: 9226934 doi: 10.1136/bmjopen-2021-052373
Nassani, R., AlAmri, H. & Alrfaei, B. M. Abstract LB183: Erythritol acts as tumor enhancer and suppressor depending on concentrations in brain tumor cell lines. Cancer Res. 81, LB183 (2021).
doi: 10.1158/1538-7445.AM2021-LB183
Kumar, V. Adenosine as an endogenous immunoregulator in cancer pathogenesis: where to go? Purinergic Signal. 9, 145–165 (2013).
pubmed: 23271562 doi: 10.1007/s11302-012-9349-9
Vigano, S. et al. Targeting adenosine in cancer immunotherapy to enhance T-cell function. Front. Immunol. 10, 925 (2019).
pubmed: 31244820 pmcid: 6562565 doi: 10.3389/fimmu.2019.00925
Chen, H. et al. Urea cycle activation triggered by host-microbiota maladaptation driving colorectal tumorigenesis. Cell Metab. 35, 651–666.e7 (2023).
pubmed: 36963394 doi: 10.1016/j.cmet.2023.03.003
Alexandrou, C. et al. Sensitivity of colorectal cancer to arginine deprivation therapy is shaped by differential expression of urea cycle enzymes. Sci. Rep. 8, 12096 (2018).
pubmed: 30108309 pmcid: 6092409 doi: 10.1038/s41598-018-30591-7
Yang, J. et al. High-fat diet promotes colorectal tumorigenesis through modulating gut microbiota and metabolites. Gastroenterology 162, 135–149.e2 (2022).
pubmed: 34461052 doi: 10.1053/j.gastro.2021.08.041
Xu, Z. et al. Dysbiosis of human tumor microbiome and aberrant residence of actinomyces in tumor-associated fibroblasts in young-onset colorectal cancer. Front. Immunol. 13, 1008975 (2022).
pubmed: 36119074 pmcid: 9481283 doi: 10.3389/fimmu.2022.1008975
Zwezerijnen-Jiwa, F. H., Sivov, H., Paizs, P., Zafeiropoulou, K. & Kinross, J. A systematic review of microbiome-derived biomarkers for early colorectal cancer detection. Neoplasia 36, 100868 (2022).
pubmed: 36566591 pmcid: 9804137 doi: 10.1016/j.neo.2022.100868
Hua, H. et al. Intestinal microbiota in colorectal adenoma-carcinoma sequence. Front. Med. 9, 888340 (2022).
doi: 10.3389/fmed.2022.888340
Gates, T. J. et al. Fecal microbiota restoration modulates the microbiome in inflammation-driven colorectal cancer. Cancers 15, 2260 (2023).
pubmed: 37190186 pmcid: 10137216 doi: 10.3390/cancers15082260
Zhang, H. et al. Disease‐associated gut microbiome and critical metabolomic alterations in patients with colorectal cancer. Cancer Med. cam4.6194. https://doi.org/10.1002/cam4.6194 (2023).
Wang, N. & Fang, J.-Y. Fusobacterium nucleatum, a key pathogenic factor and microbial biomarker for colorectal cancer. Trends Microbiol. 31, 159–172 (2023).
pubmed: 36058786 doi: 10.1016/j.tim.2022.08.010
Sobhani, I. et al. Colorectal cancer-associated microbiota contributes to oncogenic epigenetic signatures. Proc. Natl Acad. Sci. USA 116, 24285–24295 (2019).
pubmed: 31712445 pmcid: 6883805 doi: 10.1073/pnas.1912129116
Sun, J. & Kato, I. Gut microbiota, inflammation and colorectal cancer. Genes Dis. 3, 130–143 (2016).
pubmed: 28078319 pmcid: 5221561 doi: 10.1016/j.gendis.2016.03.004
Artemev, A., Naik, S., Pougno, A., Honnavar, P. & Shanbhag, N. M. The association of microbiome dysbiosis with colorectal cancer. Cureus 14, e22156 (2022).
pubmed: 35174040 pmcid: 8840808
Chen, Q. et al. Rubidium chloride modulated the fecal microbiota community in mice. BMC Microbiol. 21, 46 (2021).
pubmed: 33588762 pmcid: 7885239 doi: 10.1186/s12866-021-02095-4
Kim, D. J. et al. Colorectal cancer diagnostic model utilizing metagenomic and metabolomic data of stool microbial extracellular vesicles. Sci. Rep. 10, 2860 (2020).
pubmed: 32071370 pmcid: 7029032 doi: 10.1038/s41598-020-59529-8
Wu, J., Wu, M. & Wu, Q. Identification of potential metabolite markers for colon cancer and rectal cancer using serum metabolomics. J. Clin. Lab Anal. 34, e23333 (2020).
pubmed: 32281150 pmcid: 7439421 doi: 10.1002/jcla.23333
León-Letelier, R. A. et al. Contributions of the microbiome-derived metabolome for risk assessment and prognostication of pancreatic cancer. Clin. Chem. 70, 102–115 (2024).
pubmed: 38175578 doi: 10.1093/clinchem/hvad186
Swanton, C. et al. Embracing cancer complexity: hallmarks of systemic disease. Cell 187, 1589–1616 (2024).
pubmed: 38552609 doi: 10.1016/j.cell.2024.02.009
Singh, A. et al. DIABLO: an integrative approach for identifying key molecular drivers from multi-omics assays. Bioinformatics 35, 3055–3062 (2019).
pubmed: 30657866 pmcid: 6735831 doi: 10.1093/bioinformatics/bty1054
Cai, Z., Poulos, R. C., Liu, J. & Zhong, Q. Machine learning for multi-omics data integration in cancer. iScience 25, 103798 (2022).
pubmed: 35169688 pmcid: 8829812 doi: 10.1016/j.isci.2022.103798
Schmidt, D. R. et al. Metabolomics in cancer research and emerging applications in clinical oncology. CA Cancer J. Clin. 71, 333–358 (2021).
pubmed: 33982817 pmcid: 8298088 doi: 10.3322/caac.21670
Liu, L. & Shah, K. The potential of the gut microbiome to reshape the cancer therapy paradigm: a review. JAMA Oncol. 8, 1059 (2022).
pubmed: 35482355 doi: 10.1001/jamaoncol.2022.0494
Routy, B. et al. Fecal microbiota transplantation plus anti-PD-1 immunotherapy in advanced melanoma: a phase I trial. Nat. Med. https://doi.org/10.1038/s41591-023-02453-x (2023).
West Coast Metabolomics Center—Assays and Services. https://metabolomics.ucdavis.edu/core-services/assays-and-services .
West Coast Metabolomics Center—Metabolites. https://metabolomics.ucdavis.edu/core-services/metabolites .
Fiehn, O. Metabolomics by gas chromatography-mass spectrometry: combined targeted and untargeted profiling. Curr. Protoc. Mol. Biol. 114, 30.4.1–30.4.32 (2016).
pubmed: 27038389 doi: 10.1002/0471142727.mb3004s114
Aboud, O. et al. Application of machine learning to metabolomic profile characterization in glioblastoma patients undergoing concurrent chemoradiation. Metabolites 13, 299 (2023).
pubmed: 36837918 pmcid: 9961856 doi: 10.3390/metabo13020299
Ismail, I. T. et al. Sugar alcohols have a key role in pathogenesis of chronic liver disease and hepatocellular carcinoma in whole blood and liver tissues. Cancers 12, 484 (2020).
pubmed: 32092943 pmcid: 7072169 doi: 10.3390/cancers12020484
Miyamoto, S. et al. Systemic metabolomic changes in blood samples of lung cancer patients identified by gas chromatography time-of-flight mass spectrometry. Metabolites 5, 192–210 (2015).
pubmed: 25859693 pmcid: 4495369 doi: 10.3390/metabo5020192
Krishnapuram, B., Carin, L., Figueiredo, M. A. T. & Hartemink, A. J. Sparse multinomial logistic regression: fast algorithms and generalization bounds. IEEE Trans. Pattern Anal. Mach. Intell. 27, 957–968 (2005).
pubmed: 15943426 doi: 10.1109/TPAMI.2005.127
Chambers, L. M. et al. Disruption of the gut microbiota confers cisplatin resistance in epithelial ovarian cancer. Cancer Res. 82, 4654–4669 (2022).
pubmed: 36206317 pmcid: 9772178 doi: 10.1158/0008-5472.CAN-22-0455
Weiss, K. et al. Barrier housing and gender effects on allergic airway disease in a murine house dust mite model. Immunohorizons 5, 33–47 (2021).
pubmed: 33478982 doi: 10.4049/immunohorizons.2000096
Bolyen, E. et al. Reproducible, interactive, scalable and extensible microbiome data science using QIIME 2. Nat. Biotechnol. 37, 852–857 (2019).
pubmed: 31341288 pmcid: 7015180 doi: 10.1038/s41587-019-0209-9
Callahan, B. J. et al. DADA2: high-resolution sample inference from Illumina amplicon data. Nat. Methods 13, 581–583 (2016).
pubmed: 27214047 pmcid: 4927377 doi: 10.1038/nmeth.3869
McMurdie, P. J. & Holmes, S. phyloseq: an R package for reproducible interactive analysis and graphics of microbiome census data. PLoS ONE 8, e61217 (2013).
pubmed: 23630581 pmcid: 3632530 doi: 10.1371/journal.pone.0061217
Benjamini, Y. & Hochberg, Y. Controlling the false discovery Rate: a practical and powerful approach to multiple testing. J. R. Stat. Soc. Ser. B Methodol. 57, 289–300 (1995).
doi: 10.1111/j.2517-6161.1995.tb02031.x
R: The R Project for Statistical Computing. https://www.r-project.org/ .
Sangwan, N. & Khorana, A. Distinct intratumoral microbiome of young-onset and average-onset colorectal cancer [Data set]. Zenodo. https://doi.org/10.5281/zenodo.10401639 (2023).

Auteurs

Thejus T Jayakrishnan (TT)

Department of Hematology-Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH, USA.
Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.

Naseer Sangwan (N)

Microbial Sequencing & Analytics Resource (MSAAR), Lerner Research Institute, Cleveland Clinic, Cleveland, OH, USA.

Shimoli V Barot (SV)

Department of Hematology-Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH, USA.

Nicole Farha (N)

Department of Hematology-Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH, USA.

Arshiya Mariam (A)

Department of Quantitative Health Sciences, Lerner Research Institute, Cleveland Clinic, Cleveland, OH, USA.
Center for Quantitative Metabolic Research, Cleveland Clinic, Cleveland, OH, USA.

Shao Xiang (S)

Department of Surgery, Cleveland Clinic, Cleveland, OH, USA.

Federico Aucejo (F)

Department of Surgery, Cleveland Clinic, Cleveland, OH, USA.

Madison Conces (M)

Case Comprehensive Cancer Center, Cleveland, OH, USA.
Department of Hematology-Oncology, University Hospital Seidman Cancer Center, Cleveland, OH, USA.

Kanika G Nair (KG)

Department of Hematology-Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH, USA.
Case Comprehensive Cancer Center, Cleveland, OH, USA.
Center for Young-Onset Colorectal Cancer, Cleveland Clinic, Cleveland, OH, USA.

Smitha S Krishnamurthi (SS)

Department of Hematology-Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH, USA.
Case Comprehensive Cancer Center, Cleveland, OH, USA.
Center for Young-Onset Colorectal Cancer, Cleveland Clinic, Cleveland, OH, USA.

Stephanie L Schmit (SL)

Center for Young-Onset Colorectal Cancer, Cleveland Clinic, Cleveland, OH, USA.
Genomic Medicine Institute, Lerner Research Institute, Cleveland Clinic, Cleveland, OH, USA.
Population and Cancer Prevention Program, Case Comprehensive Cancer Center, Cleveland, OH, USA.

David Liska (D)

Case Comprehensive Cancer Center, Cleveland, OH, USA.
Center for Young-Onset Colorectal Cancer, Cleveland Clinic, Cleveland, OH, USA.
Department of Colorectal Surgery, Digestive Disease & Surgery Institute, Cleveland Clinic, Cleveland, OH, USA.

Daniel M Rotroff (DM)

Department of Quantitative Health Sciences, Lerner Research Institute, Cleveland Clinic, Cleveland, OH, USA.
Center for Quantitative Metabolic Research, Cleveland Clinic, Cleveland, OH, USA.

Alok A Khorana (AA)

Department of Hematology-Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH, USA.
Case Comprehensive Cancer Center, Cleveland, OH, USA.
Center for Young-Onset Colorectal Cancer, Cleveland Clinic, Cleveland, OH, USA.

Suneel D Kamath (SD)

Department of Hematology-Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH, USA. kamaths@ccf.org.
Case Comprehensive Cancer Center, Cleveland, OH, USA. kamaths@ccf.org.
Center for Young-Onset Colorectal Cancer, Cleveland Clinic, Cleveland, OH, USA. kamaths@ccf.org.

Classifications MeSH